The Impact of Non-bone Metastatic Cancer on Musculoskeletal Health

Current Osteoporosis Reports, Год журнала: 2024, Номер 22(3), С. 318 - 329

Опубликована: Апрель 22, 2024

Язык: Английский

Relationship between circulating FSH levels and body composition and bone health in patients with prostate cancer who undergo androgen deprivation therapy: The BLADE study

eLife, Год журнала: 2024, Номер 13

Опубликована: Апрель 24, 2024

Background: Among its extragonadal effects, follicle-stimulating hormone (FSH) has an impact on body composition and bone metabolism. Since androgen deprivation therapy (ADT) a profound circulating FSH concentrations, this could potentially be implicated in the changes of fat mass (FBM), lean (LBM), fragility induced by ADT. The objective study is to correlate serum levels with parameters, mineral density (BMD), turnover markers at baseline conditions after 12 months Methods: Twenty-nine consecutive non-metastatic prostate cancer (PC) patients were enrolled from 2017 2019 phase IV study. All underwent administration luteinizing hormone-releasing antagonist degarelix. FBM, LBM, BMD evaluated dual-energy x-ray absorptiometry FSH, alkaline phosphatase, C-terminal telopeptide type I collagen assessed 6 months. For outcome measurements statistical analysis, t -test or sign test Pearson Spearman tests for continuous variables used when indicated. Results: At conditions, weak, non-significant, direct relationship was found between FBM arms ( r = 0.36) legs 0.33). Conversely, stronger correlation observed total 0.52, p 0.006), 0.54, 0.004), trunk 0.45, 0.018) On other hand, inverse appendicular index/FBM ratio −0.64, 0.001). This ancillary prospective trial main limitation. Conclusions: ADT have composition, particular FBM. Therefore, promising marker monitor risk sarcopenic obesity guide clinicians tailored evaluation PC undergoing Funding: research partially funded Ferring Pharmaceuticals. funder had no role design conduct study, collection, management, interpretation data preparation, review, approval manuscript. Clinical number: clinicalTrials.gov NCT03202381 , EudraCT Number 2016-004210-10.

Язык: Английский

Proactive strategies for fracture risk in androgen deprivation therapy: a call for multidisciplinary collaboration

Osteoporosis International, Год журнала: 2024, Номер unknown

Опубликована: Дек. 16, 2024

Язык: Английский